The announcement in May 2016 of the partnership between Kayentis and SecureConsent was just the first step in the integration of eConsent into Kayentis eCOA solutions. Today, Kayentis and SecureConsent® strengthen their strategic alliance to enhance the benefits of this integration.
eConsent benefits already available in Kayentis eCOA solutions
- Kayentis – a global, innovative provider of eCOA solutions – and SecureConsent® – a leading provider of eICF solutions announced in May 2016 that they have built a Strategic Alliance to optimize the provision of eCOA and eICF for all stakeholders in a clinical study/programme. This alliance enables both solutions to be made available on a single tablet device, allowing the streamlining and acceleration of the setup process as well as the integration of services during study follow-up.
- Key advantages of SecureConsent® with Kayentis:
* One single tablet device for both solutions.
* The choice of both Samsung and Android makes it very robust and easy to maintain; OS upgrades are controlled.
* Kayentis tablets have worldwide 3G capacity based on an alliance with SFR/Vodafone; this ensures that the SecureConsent online solution works regardless of Wifi availability at study sites.
* Logistics are shared and managed by Kayentis.
* Tier 1 support is managed by Kayentis; teams are already trained.
And more steps are to come to improve patient engagement!
- Kayentis/SecureConsent®: an “evolving/dynamic” alliance
This strategic alliance is continually developing. The aim is to continue to strengthen eConsent integration to continually improve patient engagement and data quality.
- eConsent benefits under review for 2017 include:
* SecureConsent® training performed by Kayentis.
* Greater integration – SecureConsent® key information will become available in Clin’Form, allowing data management activities to be performed by the Kayentis team (e.g. reconciliation of subject numbers with the randomization tool).
* Single Sign On for study sites.
* Joint archiving procedures.
eConsent is a significant step forward in clinical trials and is key to the improvement of patient engagement in eCOA solutions as well as being beneficial to all stakeholders:
* Benefits for the Subjects: one single device.
* Benefits for the Sites: simpler setup and handling, a single helpdesk.
* For the Sponsors: accelerated setup, guaranteed connectivity, significant cost savings.
Guillaume JUGE, CEO – Kayentis – November 30 2016.
// Learn more about SecureConsent® //
// Contact us for more information about eICF integration in your eCOA study //
